Enrique Diloné

Chief Technology Officer, Immunitybio

Search every verified Enrique Diloné interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Enrique Diloné, Chief Technology Officer at ImmunityBio, discussed his role and the company's recent developments in a July 2024 podcast appearance. He described joining ImmunityBio ahead of the FDA approval of its immunotherapy Anktiva for non-muscle invasive bladder cancer, noting that his initial reaction to a regulatory setback involved a "sense of loss," particularly because the issue was related to chemistry, manufacturing, and controls (CMC) rather than efficacy. Diloné also spoke about his approach to leadership, emphasizing the importance of bridging different disciplines and communicating technical and regulatory matters to senior leadership in a way that builds trust. Diloné also addressed the challenges of preparing for a product launch at a company without prior experience in that area. He stated that the CTO must be involved in detailed coordination across manufacturing, quality, and supply chain units to identify bottlenecks, adding that many issues arise from processes originally designed for clinical rather than commercial scale. His comments reflect a focus on operational readiness and cross-functional collaboration as ImmunityBio moves forward with its first approved product.